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Comparison of high-performance thin layer chromatography/
UV-densitometry and UV-derivative spectrophotometry 
for the determination of trimetazidine in pharmaceutical 
formulations
New methods for assaying trimetazidine dihydrochloride 
on the basis of thin layer chromatography and spectropho-
tometry are proposed and compared in the paper. In 
HPTLC/UV-densitometry, separation is achieved by using 
a mobile phase composed of ammonia-methanol (30:70, 
V/V) on silica gel HPTLC plates F254. Quantification using 
a non-linear calibration curve is accomplished by densito-
metric detection at 230 nm. Derivative spectrophotometric 
determination of trimetazidine dihydrochloride is carried 
out from the fourth derivative of the absorbance at 233 nm 
in peak-zero mode. Statistical comparison led to the conclu-
sion that there is no significant difference between the two 
studied methods and, moreover, that they demonstrate satis-
factory accuracy and precision for routine applications.
Keywords: trimetazidine dihydrochloride, high perfor-
mance thin layer chromatography/UV-densitometry, de-
rivative spectrophotometry, pharmaceutical formulations
 
Trimetazidine (chemical name  [1-(2,3,4-trimethoxybenzyl)-piperazine], TMD), is a 
cytoprotective drug for stable angina, which may be also used for the treatment of sys-
tolic dysfunction in cardiac failure patients (1). This anti-anginal agent was developed and 
marketed in the 1970s by Laboratoires Servier but its effectiveness raised a lot of contro-
versy, to such an extent that some have gone so far as to call it a “placebo drug” (2, 3). 
Nevertheless, TMD is widely prescribed as a long-term treatment in Europe and Asia (4). 
In general, it has been treated as a highly safe and well-tolerated drug; however, in 2012, 
the European Medicines Agency (EMA) recommended some restrictions on TMD (3). 
Only a limited number of studies reported in recent years show that high perfor-
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tion of trimetazidine in pharmaceutical dosage forms; more spectrophotometric methods 
were found for the analysis of TMD (5–9). Most of those methods are based on simple UV 
spectrophotometry or require additional reagents and procedures to obtain colored prod-
ucts and consequently need ample time for execution. The primary aim of this study is to 
suggest more convenient alternatives to the above listed methods by designing procedures 
with minimum equipment, chemicals and time consumption as well as to point out the 
most suitable method for routine control of trimetazidine. Based on our previously developed 
methods (10, 11), the newly established methods involve HPTLC/UV-densitometry and 
UV-derivative spectrophotometry, which are commonly used in pharmaceutical analysis, 
mainly because of their low cost, simplicity and rapidity. The secondary aim of the study 
is to establish a method based on the fourth-order spectra for determination of TMD and 
compare it with HPTLC/UV-densitometry.
EXPERIMENTAL
Chemicals
Trimetazidine dihydrochloride ([1-(2,3,4-trimethoxybenzyl)-piperazine dihydrochlo-
ride], 97 %, used as standard, was purchased from Sigma-Aldrich (USA). Pharmaceutical 
preparation Metazydyna® (trimetazidine dihydrochloride, 20 mg) was from Polfa Pabian-
ice S.A. (Poland). Talc was obtained from Zakład Farmaceutyczny Amara (Poland). Metha-
nol, ethanol 96 %, 0.1 mol L–1 NaOH, 0.1 mol L–1 NaCl and ammonia 20 %, were all from 
Polskie Odczynniki Chemiczne S.A. (Poland). Water was prepared by means of a Milli-Q 
Water Purification System (Millipore, USA).
Apparatus
Instrumentation essential for HPTLC included: a precoated silica gel aluminium 
HPTLC plate 60 F-254 (20×20 cm, thickness 150 μm, particle size 5–7 μm; Merck, Germany), 
a horizontal DS-type chamber (Chromedes, Poland), a CD 60 HPTLC densitometer using 
ProQuant software (Desaga, Germany) for densitometric measurement and a photographic 
documentation system CabUV-Vis composed of Canon Power Shot G5 digital apparatus 
with ProViDoc 3.0 software (Desaga).
Table I. Chromatographic parameters of the HPTLC assay of TMD
Parameter Value
Rf (retardation factor, relate-to-front) / hRf (Rf multiplied by 100) 0.74 / 74
k´ (capacity factor) 0.36
SN (separation number)a 10
N (theoretical plate number) 1900
HETP (height equivalent to a theoretical plate) 47 μm
a SN – Separation number or spot capacity (maximum number of substances completely separated between Rf = 0 
and Rf = 1).
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Fig. 1. a) HPTL chromatogram of trimetazidine dihydrochloride at 230 nm with standard lines 1–8 
(1–0.25 μg, 2–0.50 μg, 3–0.75 μg, 4–1.00 μg, 5–1.25 μg, 6–1.50 μg, 7–1.75 μg, 8–2.00 μg TMD) and tablet 
extracts (lines 9–11); b) densitogram with standard lines (1–8); c) densitogram with tablet extracts 
(lines 1–3).
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For spectrophotometric measurements, a double beam UV-Vis spectrophotometer 
(Hitachi U-2800, Japan) was used to record spectra over the 190–400 nm range at 25 oC in 
a 1-cm quartz cell. UV Solutions 2.0 software was used to calculate derivative spectra (first-, 
second-, third- and fourth-order) using the Savitzky-Golay method (order = 3, ∆λ = 6 nm) 
with peak-zero (P-0), zero-peak (0-P) and peak-peak techniques of measuring.
Standard solution
Selection of solvent for analyses was based on recording and investigating the spectra 
of TMD dissolved in water, 0.1 mol L–1 HCl, 0.1 mol L–1 NaOH, ethanol and methanol. Most 
of them were eliminated because of the absorption maximum below 0.3, solution color 
after extraction from tablets or time-consuming extraction. Methanol was chosen as the 
most appropriate solvent for HPTLC as well as for spectrophotometry and time of extrac-
tion was optimized at 5 min. A quantity of 100 mg of pure TMD was dissolved in methanol 
and diluted to 100 mL in a calibrated flask giving a stock solution (1 mg mL–1) for further 
analyses. After appropriate dilutions, this stock solution was used for calibration.
Calibration
HPTLC/UV-densitometry. – Stock solution of TMD diluted to a concentration of 0.25 μg 
mL–1 was applied (lines 1–8, Fig. 1) onto the plate in the range of 0.25–2.00 μg per spot. 
After 10-min evaporation of the solvent at room temperature, a chromatogram was developed 
using the horizontal technique in the chamber saturated with the mobile phase composed 
of ammonia/methanol (30:70, V/V). Saturation time was 60 min. A chromatogram run was 
9 cm and hRf value was 74. In the next step, the separation plate was dried and after 15 
minutes, densitometric analysis was performed in the absorbance mode at a wavelength 
of 230 nm (Figs. 1a,b). All measurements were repeated six times. Finally, calibration 
curves were created as the relationship between the peak area value and drug quantity per 
spot (Table II). 
UV-derivative spectrophotometry. – Nine dilutions of the TMD stock solution in the con-
centration range of 0.25–10.0 μg mL–1 were used. Consecutive spectra were recorded by a 
double beam spectrophotometer against methanol (blank) (Fig. 2). All measurements were 
done six times for each concentration (Table III).
TMD assay in model mixtures and pharmaceutical formulation
Three laboratory prepared model mixtures were prepared by adding the TMD stan-
dard to the samples in an amount from 80 to 120 % with respect to the declared content of 
TMD in the pharmaceutical preparation Metazydyna® (20 mg). Trimetazidine dihydro-
chloride tablets Metazydyna® 20 mg were triturated and a mass equivalent to 5.00 mg of 
TMD was transferred into a volumetric flask (for model mixtures equivalent to 4.00, 5.00 
and 6.00 mg of TMD, resp.) and dissolved in 20 mL methanol (repeated six times). After 
swirling, sonification, filtration and rejection of the first portion of the filtrate, six indepen-
dent working solutions of TMD were prepared for analysis and applied onto a chromato-
graphic plate in a volume of 5 μL each line, corresponding to 1.00, 1.25 (for model mixture 
and sample of Metazydyna®) and 1.50 μg of trimetazidine per spot (80.0, 100.0, 120.0 %). 
Finally, densitometric scanning was performed under the abovementioned conditions.
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Next, for the spectrophotometric method, tablet extracts were diluted with methanol 
to approx. 5.00 μg mL–1and model mixture extracts were diluted to 4.00, 5.00 and 6.00 μg 
mL–1, resp. UV-spectra were recorded against the blank (methanol) over 190–400 nm and 
derivative spectra were subsequently calculated.
Validation of HPTLC and derivative spectrophotometry methods was performed in 
accordance with the Association of Analytical Communities (AOAC) Guidelines for Stan-
dard Method Performance Requirements (12). Accuracy of the abovementioned methods 
was assessed by recovery rates after addition of a standard on three levels into laboratory-
prepared model mixtures, and repeatability was expressed as relative standard deviation 
(RSD). Other validation parameters are limit of detection (LOD) and quantification (LOQ), 
specificity, linearity, Horwitz ratio.
Statistical testing for significant difference between the elaborated methods was per-
formed by means of t- and F-tests.
RESULTS AND DISCUSSION
In the present study, two independent analytical methods for assaying trimetazidine 
dihydrochloride in the pharmaceutical dosage form have been developed, validated and 
finally compared.
Initially, methanol was selected as the most suitable solvent for both analyses, ensur-
ing good solubility, application on chromatographic plates, effective extraction and no 
interference with TMD in absorbance measurements.
HPTLC separation was followed by a densitometric scan in order to find the analytical 
wavelength for quantitative analysis; this was 230 nm (chromatographic parameters are 
presented in Table I). For the linear model, R was 0.9750, RSD 1.0 and 2.8 %, mean recovery 
104.8 and 98.6 % for model mixtures and tablets, resp. Some findings showed that calibra-
tion curves for HPTLC, when the densitometer worked in UV or Vis, showed non-linear 
fit (13–15). On the other hand, linearity was also observed, especially after transformation 
in agreement with Lambert-Beer ś law (15). In accordance with our previous experience 
(10), relationships between the recorded peak areas and TMD quantity per spot were non-
linear (Table II). In sum, the best recovery value (101.3 %) and precision (RSD 1.3 %) were 
achieved for a quadratic equation (y = a + bx + cx2) calibration curve with R = 0.9980 (Table 
II). In addition, for quantification of TMD in tablets, the precision was also acceptable, with 
RSD 2.3 % and recovery 98.9 % (Fig. 1).
Next, the UV-derivative spectrophotometry method was applied to determine 
trimetazidine dihydrochloride in tablets. First, the zero-order spectrum (Fig. 2a) was re-
corded for 0.25–10.0 μg mL–1 of TMD with λmax = 205.5 nm. First-, second-, third- and 
fourth-derivative spectra (first- and fourth- derivatives are shown in Figs. 2b,c) were ob-
tained and measured by the peak-zero and peak-peak techniques. The vast majority of 
calculated calibration lines were characterized by satisfactory linearity (R > 0.99); only two 
were rejected. Moreover, for all curves, based on statistical testing, the intercept (b) was 
not significantly different from zero, which led to the calculation from equation y = ax. For 
most curves, the results were characterized by good precision (RSD 1.9–5.3 %). However, 
analyses of the model mixtures presented an overestimated mean recovery value for some 
of the proposed calibration curves. Namely, some curves were not appropriate for estima-
tion. Only selected derivative spectra and wavelengths gave satisfactory recovery and 
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Fig. 2. a) Zero-order, b) first- and c) fourth-order derivative spectra of trimetazidine dihydrochloride 
in the concentration range 0.25–10.0 μg mL–1 in methanol.
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might be used to establish a quantification method. The most accurate conditions were 
found for the fourth-order derivative spectrum (recovery 102.1 and 99.3 % for model mix-
tures and tablets, resp.) with mean RSD 1.9 % for model mixtures and 2.8 % for tablets as 
well as for zero-order (Table III).
No interference was observed from talc during chromatographic separation, spectro-
photometric measurement (190–400 nm) or densitometric measurement at 230 nm. Lower 
values for detection (LOD) and quantification limit (LOQ) were obtained for derivative 
spectrophotometry, making the spectrophotometric methods more sensitive than HPTLC/
UV-densitometry (Table IV) (10, 11).
Accuracy of the elaborated methods was evaluated by recovery at three levels (80.0, 
100.0, 120.0 % of the studied compound compared to the tablet label amount) and confirmed 
that both methods were reliable. Mean recovery for determination in model mixtures was 
101.3 and 102.1 % for HPTLC and spectrophotometry, resp. Precision of the estimated meth-
ods was assessed as well, with RSD values of 1.2 and 1.9 % for HPTLC and derivative spec-
trophotometry, resp. It must be emphasized that there was no significant difference between 
the elaborated methods, since the calculated t- and F-values did not surpass theoretical val-
ues at the confidence level of 95 % (Table IV). All the obtained values of HorRat (Horwitz 
ratio) were between 0.3 and 1.3 (Table IV), which means that both elaborated methods can 
be considered acceptable for single, namely, in-house, laboratory validation (12).
CONCLUSIONS
The present study demonstrates the potential application of HPTLC and derivative 
spectrophotometry methods in analyses of trimetazidine dihydrochloride in its pharma-
ceutical formulation. On the one hand, the derivative spectrophotometry method is char-
acterized by better sensitivity (lower LOD and LOQ) but, on the other hand, HPTLC/UV-
densitometry offers better recovery and precision. Nevertheless, both methods can be 
successfully applied for routine quantification of TMD and are attractive alternatives to 
methods requiring derivatization, tedious extraction, expensive reagents or instruments.








equation R HorRat t F




(4th derivative mode,  
233 nm)
0.15 0.46 y = 2 × 10–7x 0.9939 1.15
Number of determinations: n = 6; significance level p = 0.05; tabular t-factor and F-factor for the degree of freedom 
during determination of precision or accuracy: t = 2.23; F = 5.05. LOD – limit of detection, LOQ – limit of quantitation.
422
M. Gackowski et al.: Comparison of high-performance thin layer chromatography/UV-densitometry and UV-derivative spectropho-
tometry for the determination of trimetazidine in pharmaceutical formulations, Acta Pharm. 69 (2019) 413–422.
 
REFERENCES
 1.  W. C. Stanley and M. Marzilli, Metabolic therapy in the treatment of ischaemic heart disease: The 
pharmacology of trimetazidine, Fundam. Clin. Pharmacol. 17 (2003) 133–145; https://doi.org/10.1046/
j.1472-8206.2003.00154.x
 2.  P. Chrusciel, J. Rysz and M. Banach, Defining the role of trimetazidine in the treatment of cardio-
vascular disorders: some insights on its role in heart failure and peripheral artery disease, Drugs 
74 (2014) 971–980; https://doi.org/10.1007/s40265-014-0233-5 
 3.  European Medicines Agency, European Medicines Agency recommends restricting use of trimetazidine-
containing medicines, EMA/CHMP/417861/2012; EMA, London 2012, https://www.ema.europa.eu/
documents/press-release/european-medicines-agency-recommends-restricting-use-trimetazi-
dine-containing-medicines_en.pdf; last access date August 31, 2018.
 4.  Z. Liu, J. M. Chen, H. Huang, M. Kuznicki, S. Zheng, W. Sun, N. Quan, L. Wang, H. Yang, H. M. 
Guo, J. Li and J. Zhuang, The protective effect of trimetazidine on myocardial ischemia/ reperfu-
sion injury through activating AMPK and ERK signaling pathway, Metabolism 65 (2016) 122–130; 
https://doi.org/10.1016/j.metabol.2015.10.022
 5.  A. Onay-Besikci and S. A. Özkan, Trimetazidine revisited: A comprehensive review of the phar-
macological effects and analytical techniques for the determination of trimetazidine, Cardiovasc. 
Ther. 26 (2008) 147–165; https://doi.org/10.1111/j.1527-3466.2008.00043.x
 6.  T. K. Murthy, G. D. Sankar and S. R. Yarraguntla, Visible spectrophotometric methods for the 
determination of trimetazidine dihydrochloride in pharmaceutical formulations, Indian Drugs 39 
(2002) 230–233.
 7.  A. A. Chiş, F. G. Gligor, G. Cormoş, E. Curea and M. Bojiţă, Spectrophotometric method for the 
determination of amorolfine, Farmacia 58 (2010) 629–636.
 8.  S. O. Thoppil, R. M. Cardoza and P. D. Amin, Stability indicating HPTLC determination of 
trimetazidine as bulk drug and in pharmaceutical formulations, J. Pharm. Biomed. Anal. 25 (2001) 
15–20; https://doi.org/10.1016/S0731-7085(00)00440-4
 9.  L. I. Bebawy, M. F. El Tarras and S. A. El Sabour, Determination of trimetazidine dihydrochloride 
in the presence of its acid-induced degradation products, J. AOAC Int. 87 (2004) 827–833.
10.  M. Gackowski, M. Koba and K. Mądra-Gackowska, Determination of lormetazepam in tablets 
using high-performance liquid chromatography, and derivative spectrophotometry methods, J. 
Planar Chromatogr. - Mod. TLC 31 (2018) 235–242; https://doi.org/10.1556/1006.2018.31.3.9
11.  M. Gackowski, M. Koba and S. Kruszewski, Comparison of UV- and derivative-spectrophotomet-
ric and HPTLC UV-densitometric methods for the determination of amrinone and milrinone in 
bulk drugs, Curr. Pharm. Anal. 14 (2018) 1–8; https://doi.org/10.2174/1573412914666180627141659
12.  AOAC International, Guidelines for Standard Method Performance Requirements (Appendix F), AOAC 
Off. Methods Anal; AOAC Int. 2016, http://www.eoma.aoac.org/app_f.pdf; https://doi.org/10.13140/
RG.2.2.20883.89125, access date August 31, 2018.
13.  P. Rashmin, P. Mrunali, D. Nitin, D. Nidhi and P. Bharat, HPTLC method development and valida-
tion: Strategy to minimize methodological failures, J. Food Drug Anal. 20 (2012) 794–804; https://
doi.org/10.6227/jfda.2012200408
14.  M. Koba, K. Koba and T. Bączek, Determination of oxazepam in pharmaceutical formulation by 
HPTLC UV-densitometric and UV-derivative spectrophotometry methods, Anal. Lett. 42 (2009) 
1831–1843; https://doi.org/10.1080/00032710903060719
15.  B. Spangenberg, Does the Kubelka-Munk theory describe TLC evaluations correctly?, J. Planar 
Chromatogr. – Mod. TLC 19 (2006) 332–341; https://doi.org/10.1556/JPC.19.2006.5.1
